13F-HR filed by Artia Global Partners LP
Artia Global Partners LP filed this 13F-HR for the quarter ended 2024-09-30, filed 2024-11-14, with 45 holding rows worth $366,883,988.
- Accession
- 0001937964-24-000006
- Filer
- CIK 1937964
- Filed
- 2024-11-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2024
A holdings report, 45 entries on the cover page, a total value of $366,883,988 stated on the cover page (in dollars after the unit check, H1), rows summing to $366,883,988 with VALUE read as dollars as filed, 13F file number 028-23071. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| NOVO-NORDISK A S ADR | 670100205 | ADR | 741,743 | $88,319,339 | dollars as filed | |
| Eli Lilly and Company | 532457108 | COM | 92,593 | $82,031,842 | dollars as filed | |
| VIKING THERAPEUTICS INC | 92686J106 | COM | 532,879 | $33,736,569 | dollars as filed | |
| INTRA-CELLULAR THERAPIES INC | 46116X101 | COMMON STOCK | 216,519 | $15,842,695 | dollars as filed | |
| ASTRAZENECA PLC SPONSORED ADR | 046353108 | ADR | 190,752 | $14,861,488 | dollars as filed | |
| SOLENO THERAPEUTICS INC | 834203309 | COM | 274,424 | $13,855,668 | dollars as filed | |
| Eli Lilly and Company | 532457108 | COM | 15,000 | $13,289,100 | dollars as filed | put |
| ALNYLAM PHARMACEUTICALS INC COM | 02043Q107 | Stock | 35,000 | $9,626,050 | dollars as filed | |
| Vertex Pharmaceuticals Incorporated | 92532F100 | COM | 18,900 | $8,790,012 | dollars as filed | |
| VAXCYTE INC COM | 92243G108 | Stock | 76,255 | $8,713,659 | dollars as filed | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 15,138 | $8,206,007 | dollars as filed | |
| AXSOME THERAPEUTICS INC. COM | 05464T104 | Stock | 87,848 | $7,894,900 | dollars as filed | |
| PROTAGONIST THERAPEUTICS | 74366E102 | COM | 124,440 | $5,599,800 | dollars as filed | |
| NEUROCRINE BIOSCIENCES INC | 64125C109 | COM | 45,000 | $5,184,900 | dollars as filed | |
| REVOLUTION MEDICINES INC COM | 76155X100 | Stock | 95,885 | $4,348,385 | dollars as filed | |
| DYNE THERAPEUTICS INC COM | 26818M108 | Stock | 119,488 | $4,292,009 | dollars as filed | |
| VERONA PHARMA PLC | 925050106 | SPONSORED ADS | 148,590 | $4,274,934 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 80,171 | $4,005,343 | dollars as filed | |
| INSMED INC COM PAR $.01 | 457669307 | Stock | 52,939 | $3,864,547 | dollars as filed | |
| CELLDEX THERAPEUTICS INC NEW | 15117B202 | COM NEW | 75,300 | $2,559,447 | dollars as filed | |
| CRINETICS PHARMACEUTICALS INC COM | 22663K107 | Stock | 45,765 | $2,338,592 | dollars as filed | |
| IDEAYA BIOSCIENCES INC COM | 45166A102 | Stock | 62,992 | $1,995,587 | dollars as filed | |
| MEREO BIOPHARMA GROUP PLC | 589492107 | CMN | 421,359 | $1,731,785 | dollars as filed | |
| SPRINGWORKS THERAPEUTICS INC | 85205L107 | COM | 53,930 | $1,727,917 | dollars as filed | |
| NUVALENT INC COM | 670703107 | Stock | 15,437 | $1,579,205 | dollars as filed | |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 40,000 | $1,574,800 | dollars as filed | |
| CENTESSA PHARMACEUTICALS PLC | 152309100 | SPONSORED ADS | 80,380 | $1,285,276 | dollars as filed | |
| EYEPOINT INC COM NEW | 30233G209 | Stock | 156,300 | $1,248,837 | dollars as filed | |
| CHARLES RIV LABS INTL INC | 159864107 | COM | 6,305 | $1,241,896 | dollars as filed | |
| IONIS PHARMACEUTICALS INC COM | 462222100 | Stock | 30,479 | $1,220,989 | dollars as filed | |
| KEROS THERAPEUTICS INC COM | 492327101 | Stock | 20,000 | $1,161,400 | dollars as filed | |
| KURA ONCOLOGY INC COM | 50127T109 | Stock | 57,178 | $1,117,258 | dollars as filed | |
| ASCENDIS PHARMA A/S DKK 1.0 AD | 04351P101 | SPONSORED ADR | 7,440 | $1,110,866 | dollars as filed | |
| ANNEXON INC | 03589W102 | COM | 172,226 | $1,019,578 | dollars as filed | |
| CORBUS PHARMACEUTICALS | 21833P301 | COM NEW | 47,400 | $977,862 | dollars as filed | |
| SILENCE THERAPEUTICS PLC | 82686Q101 | ADS | 52,476 | $954,014 | dollars as filed | |
| SYNDAX PHARMACEUTICALS INC | 87164F105 | COM | 48,263 | $929,063 | dollars as filed | |
| NEWAMSTERDAM PHARMA CO NV | N62509109 | COMMON STOCK | 54,285 | $901,131 | dollars as filed | |
| ALECTOR INC | 014442107 | COMMON STOCK | 193,317 | $900,857 | dollars as filed | |
| DISC MEDICINE INC COM | 254604101 | Stock | 13,440 | $660,442 | dollars as filed | |
| LARIMAR THERAPEUTICS INC | 517125100 | COM | 90,490 | $592,710 | dollars as filed | |
| ACELYRIN INC | 00445A100 | COM | 93,114 | $459,052 | dollars as filed | |
| MADRIGAL PHARMACEUTICALS INC COM | 558868105 | Stock | 1,557 | $330,427 | dollars as filed | |
| SUMMIT THERAPEUTICS INC | 86627T108 | COM | 14,512 | $317,813 | dollars as filed | |
| Q32 BIO INC | 746964105 | Common Stock | 4,705 | $209,937 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001937964-24-000006 | this filing | 2024-11-14 | acceptance time not in the bulk data set |